Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.
Peter Attia
17 nov 2025
Mindsip insights from this episode:
Demand mass spectrometry for reliable T3 testing
Common lab immunoassays for T3 and especially reverse T3 are not good, particularly at low levels, and require mass spectrometry for reliable results, which is not widely available clinically.
Question the efficacy of compounded slow-release T3 formulations
There is no scientific publication showing that popular compounded "slow-release" T3 formulations actually exhibit a slow-release profile in the body.
Reevaluate radioactive iodine treatment due to cancer risk
Radioactive iodine treatment for hyperthyroidism, once a standard therapy, is now known to be associated with an increased risk of developing other types of cancer.
Reevaluate hypothyroidism treatment to reduce mortality risk
Retrospective data shows that patients treated with standard levothyroxine for hypothyroidism have a 2.5 times greater mortality rate compared to healthy controls.
Recognize TSH range increases with age for accurate health assessment
After age 50, the upper limit of the normal TSH range increases by about one point every decade, meaning a TSH of 8 can be normal for an 80-year-old.
Understand brain's local T3 production for accurate health insights
Most of the active thyroid hormone (T3) in the brain is produced locally by the D2 enzyme and does not come from the blood, explaining why blood levels don't always reflect brain status.
Implement combination therapy to lower mortality in hypothyroid patients
In a large retrospective study, hypothyroid patients on combination T4/T3 therapy had a 30% lower mortality rate than those on T4 monotherapy.
Limit iodine intake to prevent autoimmune thyroid disease
Excessive iodine intake, far above the recommended daily amount of 150 micrograms, is known to increase the incidence of autoimmune thyroid disease.
Question levothyroxine's efficacy due to lack of clinical trials
The FDA never required a single clinical trial to prove the efficacy of levothyroxine (Synthroid) for outcomes like mortality reduction before it became the standard of care.
More from
Peter Attia
The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast)
AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications
Women's sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H.
Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast)
AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?
You also might be interested in
One Fat Can Prevent Dementia — If You Eat It Long-term
This Is Why Soda Spreads Cancer in your Body
Starving Cancer: The Hidden Power of Food, Fasting, and the Body’s Inner Terrain
Dementia Rates PLUNGED in Study of 1 Million People
The Fastest Way to Get Alzheimer’s (Most People Do This Daily) | Dr. Dale Bredesen












